What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?

What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?

Background/Aim: An effective postprogression treatment of lenvatinib (LEN) against unresectable hepatocellular carcinoma (u-HCC) has not been established. We aimed to elucidate the clinical role of continuing LEN beyond progression of disease (PD). Methods: From March 2018 to October 2020, 99 u-HCC...

Full description

Bibliographic Details
Main Authors: Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Kazuya Kariyama, Joji Tani, Shinya Fukunishi, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Kazuhito Kawata, Satoshi Yasuda, Hidenori Toyoda, Hideko Ohama, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Korenobu Hayama, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Kojiro Michitaka, Yoichi Hiasa, Masatoshi Kudo
Format: Article
Language:English
Published: Karger Publishers 2021-02-01
Series:Liver Cancer
Subjects:
hepatocellular carcinoma
lenvatinib
hand-foot skin reaction
postprogression treatment
beyond progression of disease
Online Access:https://www.karger.com/Article/FullText/513355

Internet

https://www.karger.com/Article/FullText/513355

Similar Items